AbbVie Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Capital-Expenditures" stands at 1.30 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
AbbVie Inc's third quarter result of 0.504 Billion USD for the item "Capital Expenditures" represents an increase of 87.36 percent compared to it's second quarter result.
Also, AbbVie Inc's third quarter result of 0.504 Billion USD for the item "Capital Expenditures" represents an increase of 102.41 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), AbbVie Inc's third quarter result of 1.30 Billion USD for the item "Capital Expenditures" represents an increase of 24.43 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 46.28 percent compared to the value the year prior.
The 1 year change in percent is 46.28.
The 3 year change in percent is 94.17.
The 5 year change in percent is 90.47.
The 10 year change in percent is 140.56.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Capital Expenditures | 905,699,262,464.00 |
![]() | Johnson & Johnson - Capital Expenditures | 486,508,953,600.00 |
![]() | Roche Holding AG - Capital Expenditures | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Capital Expenditures | 280,205,508,085.11 |
![]() | Novartis AG - Capital Expenditures | 255,096,620,580.91 |